ARWR Stock Arrowhead Pharmaceuticals, Inc.
US · NasdaqGSLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
RNAi pipeline catalysts create asymmetric upside if late-stage programs continue delivering clinical progress.
Future value: $109.00 (+85.00%) · 6-12 months
Signal breakdown
- ▸Consensus Strong Buy with multiple Buy ratings.
- ▾Below 50-day MA (-20.76%)
- ▸~85% upside to price target
Is ARWR a buy right now?
Trend: ARWR is trading below the 50-day average (-18.16%), RSI 50 — neutral momentum, with a 3-month return of -31.24%.
Valuation & quality: Arrowhead Pharmaceuticals, Inc. trades on forward P/E -11.8, price-to-book 17.88; fundamentals show net margin -47.8%, return on equity -55.2%, revenue growth 171.0% year on year.
Analyst consensus: 14 analysts have a mean 12-month price target of $107.71 (+82.6% vs the last close; range $74.00 – $126.00), consensus rating “strong buy”.
Our screen: BUY (score 3) — RNAi pipeline catalysts create asymmetric upside if late-stage programs continue delivering clinical progress.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -0.90% | +17.20% | +6.00% | +4.60% | +3.90% | -2.70% | -20.60% | -9.90% |
Fundamentals
Analyst price target
Technical signals
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 711 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.